Overview

Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis

Status:
Completed

Trial end date:
2017-12-28

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to determine the pediatric dose of delamanid that is equivalent to the adult dose already shown to be effective against multidrug-resistant tuberculosis.

Phase:

Phase 1

Details

Lead Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.